These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
172 related items for PubMed ID: 6096585
41. [Clinical and bacteriological studies of ceftriaxone (CTRX) once daily administration in pediatric patients with respiratory tract infections]. Hasui M, Kobayashi Y, Harada Y, Ono A, Okazaki H, Kino M, Hara T. Jpn J Antibiot; 2001 Oct; 54(10):532-40. PubMed ID: 11771335 [Abstract] [Full Text] [Related]
42. [Causative organisms of acute otitis media and acute sinusitis in children and their susceptibility of oral beta-lactam antibiotics]. Takenaka M, Morikawa Y, Nakagawa T, Takashima T, Haruta T, Tsuji T. Jpn J Antibiot; 1999 Feb; 52(2):162-71. PubMed ID: 10221181 [Abstract] [Full Text] [Related]
43. [Clinical evaluation of ceftriaxone in the pediatric field]. Minamitani M, Hachimori K, Kaneda K. Jpn J Antibiot; 1984 Dec; 37(12):2283-97. PubMed ID: 6098721 [Abstract] [Full Text] [Related]
44. [Comparison of in vitro activity of first, second and third generation cephem antibiotics against various pathogens isolated from clinical materials in 1983]. Matsuo K, Tsuzaki Y, Furukawa S, Uete T. Jpn J Antibiot; 1984 Jun; 37(6):1040-57. PubMed ID: 6387213 [Abstract] [Full Text] [Related]
45. [Susceptibilities of bacteria isolated from patients with lower respiratory infectious diseases to antibiotics (1997)]. Ikemoto H, Ito C, Yoshida T, Watanabe K, Mori T, Ohno I, Okada S, Igari J, Arakawa M, Igarashi K, Oguri T, Okada M, Ozaki K, Terai T, Aoki N, Inoue H, Nakadate T, Kitamura N, Sekine O, Suzuki Y, Ando M, Suga M, Sato K, Nakata K, Kusano N. Jpn J Antibiot; 1999 May; 52(5):353-97. PubMed ID: 10480048 [Abstract] [Full Text] [Related]
46. [Susceptibilities of bacteria isolated from patients with respiratory infectious diseases to antibiotics (1992)]. Ikemoto H, Watanabe K, Mori T, Igari J, Oguri T, Kobayashi K, Satou K, Matsumiya H, Saito A, Terai T, Tanno Y, Nishioka K, Arakawa M, Wada K, Okada M, Ozaki K, Aoki N, Kitamura N, Sekine O, Suzuki Y, Tanimoto H, Nakata K, Nakamori Y, Nakatani T, Kusano N. Jpn J Antibiot; 1996 Jan; 49(1):34-70. PubMed ID: 8851305 [Abstract] [Full Text] [Related]
47. [Clinical laboratory approach for estimating effective administrative dosage of cefmenoxime. Observation on the MICS and cefmenoxime disc susceptibility test]. Uete T, Matsuo K. Jpn J Antibiot; 1984 May; 37(5):791-801. PubMed ID: 6090721 [Abstract] [Full Text] [Related]
48. [Antibacterial activity of ceftriaxone against various clinical strains isolated in 2004]. Matsuzaki K, Shito K, Watabe E, Hasegawa M, Sato Y, Kobayashi I. Jpn J Antibiot; 2005 Jun; 58(3):283-9. PubMed ID: 16161754 [Abstract] [Full Text] [Related]
49. [Clinical and pharmacokinetic study of ceftriaxone in pediatric bacterial infections]. Meguro H, Nonaka C, Kawaoi T, Takahashi S, Fujii R, Arimasu O. Jpn J Antibiot; 1984 Nov; 37(11):2049-59. PubMed ID: 6098701 [Abstract] [Full Text] [Related]
50. [Sensitivity of the recent bacterial isolates to cefotaxime and other cephem antibiotics]. Fujita S, Yoshida T, Okado N, Matsubara F. Jpn J Antibiot; 1983 Oct; 36(10):2887-92. PubMed ID: 6325747 [Abstract] [Full Text] [Related]
51. Antimicrobial activity of ceftriaxone: a review. Cleeland R, Squires E. Am J Med; 1984 Oct 19; 77(4C):3-11. PubMed ID: 6093515 [Abstract] [Full Text] [Related]
52. [Susceptibility of clinical isolates to cefotaxime]. Asari S, Horikawa M, Tsukamoto H, Hayashi C, Miyai K. Jpn J Antibiot; 1983 Feb 19; 36(2):277-89. PubMed ID: 6304369 [Abstract] [Full Text] [Related]
53. In vitro synergy and potentiation between cefotaxime and desacetylcefotaxime against clinical isolates of Bacteroides. Aldridge KE, Sanders CV, Marier RL. Diagn Microbiol Infect Dis; 1984 Jun 19; 2(3 Suppl):47S-53S. PubMed ID: 6086218 [Abstract] [Full Text] [Related]
54. Pharmacokinetics of cefotaxime and desacetylcefotaxime in the newborn. Aujard Y, Brion F, Jacqz-Aigrain E, Kasse MC, Chretien P, Criqui C, Mathieu H. Diagn Microbiol Infect Dis; 1989 Jun 19; 12(1):87-91. PubMed ID: 2653716 [Abstract] [Full Text] [Related]
55. Cefotaxime and desacetylcefotaxime: an example of advantageous antimicrobial metabolism. Chin NX, Neu HC. Diagn Microbiol Infect Dis; 1984 Jun 19; 2(3 Suppl):21S-31S. PubMed ID: 6086215 [Abstract] [Full Text] [Related]
56. [Antibiotic susceptibility of Neisseria meningitidis from healthy and diseased persons in Japan]. Watanabe Y, Takahashi C, Ohya H, Okazaki N, Onoue Y. Kansenshogaku Zasshi; 2007 Nov 19; 81(6):669-74. PubMed ID: 18095464 [Abstract] [Full Text] [Related]
57. Antimicrobial susceptibility of respiratory Haemophilus influenzae strains isolated from pediatric respiratory tract infections. Cao LD, Naruhiko I, Nobue T, Yoichi K. Pediatr Int; 2004 Aug 19; 46(4):419-24. PubMed ID: 15310306 [Abstract] [Full Text] [Related]
58. [Antimicrobial activity of cefodizime against clinical isolates]. Suzuki Y, Ishihara R, Ishii Y, Nakazawa A, Deguchi K, Matsumoto Y, Nishinari C, Nakane Y, Fukumoto T. Jpn J Antibiot; 1996 Oct 19; 49(10):947-65. PubMed ID: 8986558 [Abstract] [Full Text] [Related]
59. Comparative pharmacokinetics of cefotaxime and ceftizoxime and the role of desacetylcefotaxime in the antibacterial activity of cefotaxime. Quintiliani R, Nightingale CH, Tilton R. Diagn Microbiol Infect Dis; 1984 Jun 19; 2(3 Suppl):63S-70S. PubMed ID: 6086220 [Abstract] [Full Text] [Related]
60. [Pharmacokinetic, bacteriological and clinical studies of SY5555 in the pediatric field]. Motohiro T, Handa S, Yamada S, Oki S, Yoshinaga Y, Oda K, Sakata Y, Kato H, Yamashita F, Imai S. Jpn J Antibiot; 1995 Feb 19; 48(2):238-60. PubMed ID: 7745814 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]